Patricia Inácio, PhD, science writer —

Adding Xpovio (selinexor) to Velcade (bortezomib) and low-dose dexamethasone significantly extends survival without signs of disease worsening in people with multiple myeloma who received one to three prior lines of therapy, top-line results from the BOSTON Phase 3 trial show. The triple combo, given…

Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive distribution agreement announced by the treatment’s maker, Karyopharm Therapeutics. Under the agreement, Promedico has exclusive rights to commercialize Xpovio in these territories, and will carry…

KP1237, an experimental therapy by Kleo Pharmaceutical that harnesses the body’s natural antibodies to fight cancers, will soon enter clinical testing for multiple myeloma, now that the U.S. Food and Drug Administration has granted it investigational new drug status. The upcoming, single-arm trial will…

The U.S. Food and Drug Administration (FDA) has granted priority review status to GlaxoSmithKline‘s application seeking the approval of belantamab mafodotin for the treatment of heavily treated multiple myeloma patients, the company announced in a press release. The biologics license application (BLA) is specifically asking for belantamab’s approval…

The European Commission has approved Darzalex (daratumumab), in combination with standard pre-transplant therapy, to treat newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant (ASCT). The decision follows a positive opinion issued by the Committee for Medicinal Products for…

The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Darzalex (daratumumab), in combination with standard pre-transplant therapy, for the treatment of newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplant (ASCT). The recommendation, based on data from the CASSIOPEIA Phase 3…

Adding the antibody Darzalex (daratumumab) to Venclexta (venetoclax), a lymphoma and leukemia treatment, is a promising approach for multiple myeloma patients who failed prior treatment, particularly those with a common genetic abnormality called t(11;14), new Phase 1/2 data show. The combination reduced tumor burden in nearly all…

Venclexta (venetoclax), approved to treat lymphoma and leukemia, may also be promising for multiple myeloma patients who failed at least one prior treatment, particularly those with a common genetic abnormality called t(11;14) or with high levels of the cell survival protein BCL2, data from two studies suggest.

The U.S. Food and Drug Administration (FDA) has granted orphan drug status to Teneobio‘s bispecific antibody TNB-383B as a possible treatment of multiple myeloma. Orphan drug designation provides Teneobio with benefits, including financial incentives for therapy development and commercialization, should it be approved. It also provides U.S. market exclusivity for…

Multiple myeloma patients who failed to respond to treatment with oral Revlimid (lenalidomide) may benefit from by being treated soon afterward with oral Pomalyst (pomalidomide) and low-dose dexamethasone, results of a Phase 2 clinical trial in a first patient group suggest. An overall response “was achieved by…